caffeine has been researched along with Hepatitis C in 5 studies
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigates the involvement of liver dysfunction in the modulation of paracetamol pharmacokinetic profile in genotype-4 HCV patients treated with either paracetamol alone (Para) or in combination with caffeine (Para-Caf)." | 9.22 | Bioavailability of paracetamol with/without caffeine in Egyptian patients with hepatitis C virus. ( Abdel-Aziz, AA; Ashour, AA; Atta, R; Botros, SS; El-Lakkany, NM; Hendawy, AS; Mansour, AM; Seif El-Din, SH, 2016) |
| "The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0." | 6.55 | Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. ( Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017) |
| "Hepatitis C is considered the major cause of cirrhosis and hepatocellular carcinoma." | 5.42 | Caffeine inhibits hepatitis C virus replication in vitro. ( Batista, MN; Braga, AC; Carneiro, BM; Rahal, P, 2015) |
| "This study investigates the involvement of liver dysfunction in the modulation of paracetamol pharmacokinetic profile in genotype-4 HCV patients treated with either paracetamol alone (Para) or in combination with caffeine (Para-Caf)." | 5.22 | Bioavailability of paracetamol with/without caffeine in Egyptian patients with hepatitis C virus. ( Abdel-Aziz, AA; Ashour, AA; Atta, R; Botros, SS; El-Lakkany, NM; Hendawy, AS; Mansour, AM; Seif El-Din, SH, 2016) |
| "Caffeine clearance has been determined in 117 volunteers and patients (including 27 patients with liver cirrhosis) after oral application of 366." | 3.67 | [One point determination of oral caffeine clearance in patients with liver diseases]. ( Brachtel, D; Epping, J; Hofstetter, G; Joeres, R; Junggeburth, J; Klinker, H; Richter, E; Zilly, W, 1988) |
| "The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0." | 2.55 | Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. ( Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017) |
| "Hepatitis C is considered the major cause of cirrhosis and hepatocellular carcinoma." | 1.42 | Caffeine inhibits hepatitis C virus replication in vitro. ( Batista, MN; Braga, AC; Carneiro, BM; Rahal, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista, MN | 1 |
| Carneiro, BM | 1 |
| Braga, AC | 1 |
| Rahal, P | 1 |
| Xu, H | 1 |
| Yu, G | 1 |
| Sun, H | 1 |
| Lv, J | 1 |
| Wang, M | 1 |
| Kong, F | 1 |
| Zhang, M | 1 |
| Chi, X | 1 |
| Wang, X | 1 |
| Wu, R | 1 |
| Gao, X | 1 |
| Zhong, J | 1 |
| Sun, B | 1 |
| Jiang, J | 1 |
| Pan, Y | 1 |
| Niu, J | 1 |
| El-Lakkany, NM | 1 |
| Hendawy, AS | 1 |
| Seif El-Din, SH | 1 |
| Ashour, AA | 1 |
| Atta, R | 1 |
| Abdel-Aziz, AA | 1 |
| Mansour, AM | 1 |
| Botros, SS | 1 |
| Wijarnpreecha, K | 1 |
| Thongprayoon, C | 1 |
| Ungprasert, P | 1 |
| Richter, E | 1 |
| Brachtel, D | 1 |
| Hofstetter, G | 1 |
| Joeres, R | 1 |
| Klinker, H | 1 |
| Junggeburth, J | 1 |
| Epping, J | 1 |
| Zilly, W | 1 |
1 review available for caffeine and Hepatitis C
| Article | Year |
|---|---|
Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis.
Topics: Administration, Oral; Beverages; Caffeine; Central Nervous System Stimulants; Chi-Square Distributio | 2017 |
1 trial available for caffeine and Hepatitis C
| Article | Year |
|---|---|
Bioavailability of paracetamol with/without caffeine in Egyptian patients with hepatitis C virus.
Topics: Acetaminophen; Adult; Aged; Analgesics; Arabs; Biological Availability; Caffeine; Female; Hepatitis | 2016 |
3 other studies available for caffeine and Hepatitis C
| Article | Year |
|---|---|
Caffeine inhibits hepatitis C virus replication in vitro.
Topics: Antiviral Agents; Apoptosis; Caffeine; Cell Cycle Checkpoints; Cell Line; Cell Survival; Hepacivirus | 2015 |
Use of parenteral caffeinum natrio-benzoicum: an underestimated risk factor for HCV transmission in China.
Topics: Adult; Age Factors; Caffeine; China; Coinfection; Cross-Sectional Studies; Female; Genotype; Hepaciv | 2015 |
[One point determination of oral caffeine clearance in patients with liver diseases].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Caffeine; Female; Hepatitis B; Hep | 1988 |